Lung Cancer
114,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
57 °P sammeln
  • Gebundenes Buch

This book provides a comprehensive yet succinct update for the clinician in the diagnosis, staging, and treatment of lung cancer. Lung cancer is a leading cause of death in the US and worldwide and its prevention, screening, and treatment is a large part of clinical practice across specialties. Frequent updates in recommendations and guidelines in screening, diagnosis, staging, treatment, and management are vital, and it can be difficult for the busy clinician to stay up to date. This book provides a comprehensive update for the chest clinician across the continuum of lung cancer care.
Each…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book provides a comprehensive yet succinct update for the clinician in the diagnosis, staging, and treatment of lung cancer. Lung cancer is a leading cause of death in the US and worldwide and its prevention, screening, and treatment is a large part of clinical practice across specialties. Frequent updates in recommendations and guidelines in screening, diagnosis, staging, treatment, and management are vital, and it can be difficult for the busy clinician to stay up to date. This book provides a comprehensive update for the chest clinician across the continuum of lung cancer care.

Each of the thirteen chapters covers a specific component of lung cancer care and is written by experts in the field who are practicing clinicians. The objectives are to provide an organized and easily-referenced resource for the chest clinician; to provide comprehensive evidence-based information on the following topics: lung cancer screening and prevention, approach to lung nodules, diagnosis and staging of lung cancer, treatment of lung cancer, pleural disease in lung cancer, and treatment complications; and to provide source information for clinicians so they can stay up-to-date on any new guidelines or recommendations related to lung cancer screening, tobacco treatment, staging, and diagnosis. This book is written specifically for the busy clinician that focuses on clinically relevant and evidence-based principles around lung cancer while providing references for ease of finding source information to enable clinicians to stay updated as guidelines change.

This is an ideal guide for practicing pulmonary clinicians, practicing general practice clinicians, trainees in chest and general medicine, as well as some advanced practice providers who need a refresher.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. MacRosty is an Assistant Professor of Medicine in the division of Pulmonary Diseases and Critical Care Medicine at the University of North Carolina at Chapel Hill and is the Associate Director of the Interventional Pulmonology Fellowship Program. She is a practicing interventional pulmonologist and sees patients within the Multidisciplinary Thoracic Oncology Program (MTOP) at UNC. She is involved in leadership roles with the American Thoracic Society, the American College of Chest Physicians as well as within UNC. Dr. MacRosty is director of UNC's clinical pleural disease service and the bronchoscopic lung volume reduction program. Her research focuses on clinical outcomes in malignant pleural disease and translational and clinical research in interventional therapies for obstructive lung diseases. She is also involved with procedural education and designing curricula for trainees in Interventional Pulmonology and Pulmonary and Critical Care Medicine.   Dr. Rivera is a Professor of Medicine and Chief of the division of Pulmonary and Critical Care Medicine at the University of Rochester in Rochester, New York. Before transitioning to URMC, she was at the University of North Carolina (UNC) in Chapel Hill. She was instrumental in developing the UNC Multidisciplinary Thoracic Oncology Program (MTOP) and the Multidisciplinary Lung Cancer Screening Program, and co-developed the North Carolina Lung Cancer Screening Registry. Through NIH/NCI funding, she collaborates with colleagues at UNC to study lung cancer screening implementation and the impact of comorbidities on lung cancer screening outcomes. Other research interests include genetic risk assessment, disparities in lung cancer care, immune-checkpoint inhibitor-related pneumonitis, appropriate staging, and molecular biomarker testing in advanced lung cancer. Dr. Rivera holds multiple leadership roles at professional societies, including President of the American Thoracic Society (2023-2024) and Chair and co-Chair of several Task Forces in the American Cancer Society National Lung Cancer Round Table (NLCRT).